13 results on '"Ghimenton C"'
Search Results
2. [Extracapillary proliferative glomerulonephritis and pulmonary purpura in a patient with rheumatoid arthritis treated with gold salts]
- Author
-
Bontempini, L., Colombari, R., Lupo, Antonio, Malena, M., Doglioni, C., and Ghimenton, C.
- Subjects
Arthritis, Rheumatoid ,Lung Diseases ,renal disease ,glomerulonephritis ,extracapillary ,Glomerulonephritis ,Humans ,Female ,Gold ,Middle Aged ,Gold Sodium Thiosulfate ,Purpura - Published
- 1986
3. Ependymoma with diffuse signet-ring features: Report of a case and review of the literature
- Author
-
Cima, L., Beccari, S., Ghimenton, C., Pinna, G., Beltramello, A., Chilosi, M., Matteo BRUNELLI, and Eccher, A.
- Subjects
Brain Neoplasms ,Signet-ring cell ,Biopsy ,Frozen sections ,Small biopsies ,Middle Aged ,Immunohistochemistry ,Magnetic Resonance Imaging ,Ependymoma ,Metastatic adenocarcinoma ,Diagnosis, Differential ,Predictive Value of Tests ,Biomarkers, Tumor ,Humans ,Female ,Carcinoma, Signet Ring Cell - Abstract
Signet-ring cell ependymoma is a rare variant of ependymoma with only seven cases described in literature. Biological behavior and prognosis of this entity are not well-known until now. We present a case of a 49-year-old female with a history of headache and gait instability. Magnetic resonance imaging showed an upper cervical tumor with cystic component and mural nodule. The patient underwent surgery. Microscopically some cells displayed an eccentric nucleus compressed to the periphery by vacuolated cytoplasm. Perivascular pseudorosettes and ependymal rosettes were seen only focally. The cells were positive for glial fibrillary acidic protein and epithelial membrane antigen. The diagnosis was ependymoma with diffuse signet-ring features, grade II according to the World Health Organization. It may be difficult to diagnose this unusual variant of ependymoma especially on small biopsies or frozen sections. A complete examination of the specimen is recommended with immunohistochemical confirmation to rule out potential morphologic mimics, such as metastatic adenocarcinomas and gliomas in the differential diagnosis.
4. LC3B and ph-S6K are both expressed in epithelioid and classic renal angiomyolipoma: A rationale tissue-based evidence for combining use of autophagic and mTOR targeted drugs
- Author
-
Fiorini, C., Brunelli, M., Cima, L., Eccher, A., Boschiero, L., Carraro, A., Gianluigi Zaza, Artibani, W., Porcaro, A. B., Cacciamani, G., Tedeschi, U., Montin, U., Violi, P., Ghimenton, C., Burato, G., Iacovelli, R., Pedron, S., Chilosi, M., and Martignoni, G.
- Subjects
autophagy ,Renal angiomyolipoma ,mTOR ,ph-S6K ,Renal angiomyolipoma, tuberous sclerosis complex, autophagy, ph-S6K, mTOR, LC3B ,tuberous sclerosis complex ,LC3B
5. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy
- Author
-
Porcaro, A. B., Ghimenton, C., Petrozziello, A., Sava, T., Migliorini, F., Romano, M., Beatrice CARUSO, Cocco, C., Antoniolli, S. Z., Lacola, V., Rubilotta, E., and Monaco, C.
- Subjects
Male ,Estradiol (E2) ,luteinizing hormone (LH) ,Testis ,Cluster Analysis ,Humans ,Testosterone ,Aged ,Retrospective Studies ,Prostatectomy ,Estradiol ,Carcinoma ,Prostate ,Prostatic Neoplasms ,Organ Size ,Luteinizing Hormone ,Middle Aged ,Prostate-Specific Antigen ,prostate cancer ,Prolactin ,Tumor Burden ,prolactin (PRL) ,total testosterone (TT) ,free-testosterone (FT) ,prostate-specific antigen (PSA) ,Pituitary Gland ,Disease Progression ,Follicle Stimulating Hormone ,Neoplasm Grading - Abstract
To evaluate estradiol (E(2)) physiopathology along the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer (PC) and subsequent cluster selection of the patient population.Records of the diagnosed (n=105) and operated (n=91) patients were retrospectively reviewed. Age, percentage of positive cores at-biopsy (P+), biopsy Gleason score (bGS), E(2), prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (TT), free-testosterone (FT), prostate-specific antigen (PSA), pathology Gleason score (pGS), estimated tumor volume in relation to percentage of prostate volume (V+), overall prostate weight (Wi), clinical stage (cT), biopsy Gleason pattern (bGP) and pathology stage (pT), were the investigated variables. None of the patients had previously undergone hormonal manipulations. E(2) correlation and prediction by multiple linear regression analysis (MLRA) was performed. At diagnosis, the log E(2)/log bGS ratio clustered the population into groups A (log E(2)/log bGS ≤ 2.25), B (2.25log E(2)/log bGS ≤ 2.48) and C (2.48log E(2)/log bGS ≤ 2.59). The operated population was clustered according to the log E(2)/log pGS ratio into groups A (log E(2)/log pGS ≤ 2.25), B (2.25log E(2)/log pGS ≤ 2.48) and C (2.48log E(2)/log pGS ≤ 2.59). Simple linear regression analysis of bGS and pGS predicting E(2) was computed; differences between the clusters were assessed by analysis of variance (ANOVA) and by contingency tables.At diagnosis, E(2) was correlated to TT (r=0.32, p=0.0006) and FT (r=0.25, p=0.0009); moreover, E(2) was independently-predicted by TT (p=0.009) and bGS (p=0.04) on MLRA. The bGS significantly predicted E(2) in all groups. Groups A, B and C differed in mean values for E(2) (p0.0001), TT (p=0.005), FT (p=0.05), P+ (p=0.01) and bGS (p=0.003); moreover, the frequencies of the different bGPs were significantly different in the three groups (p=0.004). Interestingly, groups A, B, and C were associated with high-, intermediate- and low-bGS tumor grade, as well as with low-, intermediate- and high-serum levels of E(2), TT and FT, respectively. In the operated population, E(2) significantly correlated to FSH (r=-0.20, p=0.04), TT (r=0.34, p=0.0008), FT (r=0.29, p=0.003), bGS (r=0.22, p=0.03) and V+ (r=0.26, p=0.01); moreover, E(2) was independently-predicted by TT (p=0.05) and bGS (p=0.03) on MLRA. The pGS significantly predicted E(2) in all groups that differed for mean values of E(2) (p0.0001), TT (p=0.004), FT (p=0.002) and pGS (p=0.007), as well as for pT (p0.0001) and pGS (p=0.008) frequencies. Interestingly, clusters A, B, and C were associated with high-, intermediate- and low-pGS-pT frequencies as well as with low-, intermediate- and high-mean serum levels of E(2), TT and FT, respectively.In a diagnosed- and operated-PC population, E(2) serum levels were functionally related along the pituitary-testis-prostate cancer axis; also the log E(2)/log bGS and log E(2)/log pGS ratio, clustered the population in three groups where the risk of progression might be ranked as high (group A), intermediate (group B) and low (group C). However, further confirmatory studies are needed.
6. Secondary amyloidosis and cystic fibrosis. A morphological and histochemical study of five cases
- Author
-
Bontempini, L., Ghimenton, C., Colombari, R., Malena, M., Iuzzolino, P., Canciani, M., Claudio DOGLIONI, and Sbabo, L.
- Subjects
6 - Ciencias aplicadas::61 - Medicina [CDU] ,Amyloidosis ,Cystic fibrosis - Abstract
The pathological findings of five cases of amyloidosis associated with Cystic Fibrosis are reported. Rectal biopsy led to the diagnosis of amyloidosis in four patients. In three cases the diagnosis was confirmed at autopsy , with involvement of spleen, liver, kidneys, adrenal glands, thyroid and other organs. It seems that Secondary Amyloidosis provokes a significant, although rare, complication of Cystic Fibrosis as greater numbers of these patients survive into adulthood.
7. Investigative clinical study on prostate cancer part VIII: Prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy
- Author
-
Ab, Porcaro, Ghimenton C, Petrozziello A, Migliorini F, Romano M, Sava T, Caruso B, Cocco C, Antonio Porcaro, Lacola V, Rubilotta E, Monaco C, and Comunale L
- Subjects
Male ,Prostatectomy ,Prolactin hormone (PRL) ,luteinizing hormone (LH) ,total testosterone (TT) ,free testosterone (FT) ,prostate-specific antigen (PSA) ,prostate cancer (PC) ,Prostate ,Prostatic Neoplasms ,Luteinizing Hormone ,Prostate-Specific Antigen ,Prolactin ,Pituitary Gland ,Testis ,Humans ,Testosterone ,Retrospective Studies - Abstract
To evaluate the prolactin hormone (PRL) physiopathology along the pituitary testicular prostate axis at the time of initial diagnosis of prostate cancer and the subsequent cluster selection of the patient population after radical prostatectomy in relation to clinical and pathological variables.Ninety-two operated prostate cancer patients were retrospectively reviewed. No patient had previously received hormonal treatment. The investigated variables included PRL, follicle stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), total prostate specific antigen (PSA), percentage of positive cores at transrectal ultrasound scan biopsy (TRUSB) (P+), biopsy Gleason score (bGS), pathology Gleason score (pGS), estimated tumor volume in relation to percentage of prostate volume (V+), overall prostate weight (Wi) and age. Empirical PRL correlations and multiple linear predictions were investigated along the pituitary testis prostate axis in the different groups of the prostate cancer population and clustered according to pT (2a/b, 3a, 3b/4) status. The patient population was classified according to the log(10) PRL/V+ ratio and clustered as follows: group A (log(10) PRL/V+ ≤1.5), B (1.5log(10)PRL/V+ ≤2.0) and C (log(10) PRL/V+2.0). Simple linear regression analysis of V+ predicting PRL was computed for assessing the clustered model and analysis of variance was performed for assessing significant differences between the groups.PRL was independently predicted by FSH (p=0.01), LH (p=0.008) and P+ (p=0.06) in low-stage prostate cancer (pT2a/b). Interestingly, PRL was independently predicted by LH (p=0.03) and FSH, TT, FT, PSA, bGS, pGS, V+, Wi and age (all at p=0.01) in advanced stage-disease (pT3b/4). V+ was also significantly correlated (r=0.47) and predicted by P+ (p0.0001) in the prostate cancer population. PRL was significantly correlated and predicted by V+ when the patient population was clustered according to the log(10)PRL/V+ ratio in group A (p=0.008), B (p0.0001) and C (p0.0001). Moreover, the three groups had significantly different mean values of PRL (p0.0001), PSA (p=0.007), P+ (p=0.0001), V+ (p0.0001), Wi (p=0.03), bGS (p=0.008), pGS (p=0.003); also, groups A, B and C had significant different pGS (p=0.03), pT (p=0.0008) and pR (p=0.01) frequency distributions.At diagnosis, in an operated prostate cancer population, PRL was significantly correlated and independently predicted along the pituitary testis prostate axis in high-stage disease; V+ was also significantly correlated and predicted by P+. Because of the high correlation and prediction of PRL by both V+ and P+, the prostate cancer population at diagnosis was clustered according to the log(10)PRL/V+ ratio into groups A, B and C that, in theory, might be models with prognostic potential and clinical applications in the prostate cancer population. However, confirmatory studies are needed.
8. Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma
- Author
-
Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, Artibani W, Antonio Porcaro, Bimbatti D, Modena A, Sava T, Tortora G, Cheng L, Eccher A, Cima L, Pedron S, Ghimenton C, Martignoni G, and Brunelli M
9. Oil Red O Is a Useful Tool to Assess Donor Liver Steatosis on Frozen Sections During Transplantation
- Author
-
Giulio Riva, Luca Novelli, Manuela Villanova, Alessandro D'Errico, Umberto Montin, Albino Eccher, M Crestani, Claudio Ghimenton, Luca Cima, Romano Colombari, Sokol Sina, Matteo Brunelli, C Bronzoni, Riva, G., Villanova, M., Cima, L., Ghimenton, C., Bronzoni, C., Colombari, R., Crestani, M., Sina, S., Brunelli, M., D'Errico, A., Montin, U., Novelli, L., and Eccher, A.
- Subjects
Male ,Biopsy ,medicine.medical_treatment ,H&E stain ,Transplants ,Transplant ,Liver transplantation ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Frozen Sections ,Transplantation, Homologou ,RISK ,OUTCOMES ,medicine.diagnostic_test ,Fatty liver ,MACROVESICULAR STEATOSIS ,Frozen Section ,Tissue Donors ,Italy ,030220 oncology & carcinogenesis ,Liver biopsy ,GRAFTS ,Female ,030211 gastroenterology & hepatology ,Human ,Adult ,medicine.medical_specialty ,Tissue Donor ,Azo Compound ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Oil Red O ,HEPATIC STEATOSIS ,Transplantation ,FATTY LIVER ,Staining and Labeling ,business.industry ,medicine.disease ,Liver Transplantation ,Fatty Liver ,chemistry ,Surgery ,Steatosis ,business ,Azo Compounds - Abstract
Oil Red O is a useful tool to assess donor liver steatosis on frozen sections during transplantation. Steatosis is a frequent finding in liver evaluation during transplantation, accounting for 9% to 26% of biopsied donor liver. The degree of macrovesicular steatosis is classified as mild, moderate, and severe; the latter is considered an absolute contraindication to liver transplantation because it is associated with poor allograft outcome. Because of the scarcity of organs, there is a debate whether livers with less severe macrovesicular steatosis are still suitable for transplant. Consequently, tools or methods that allow a more accurate intraoperative assessment of steatosis on frozen sections are mandatory. The aim of this study is to improve intraoperative evaluation of steatosis during transplantation using Oil Red O stain on liver biopsies. Methods Twenty consecutive liver biopsies of donors were collected during transplantation procedures from September 2017 to February 2018 at the Institute of Pathology of the University and Hospital Trust of Verona, Italy. Each liver biopsy was cut at a different thickness (3, 5, and 8 μm) and stained with both Oil Red O and conventional hematoxylin and eosin for intraoperative consultation. The degree (percentage of hepatocytes involved) of fatty changes was recorded. The results obtained during the intraoperative consultation were finally compared with the formalin-fixed and paraffin-embedded permanent section. Results Assessment of steatosis on hematoxylin and eosin frozen sections was reported as mild in 17 cases (85%), moderate in 2 cases (10%) and severe in 1 case (5%). Oil Red O frozen sections reported the following results: mild steatosis in 16 cases (80%), moderate in 2 cases (10%), and severe in 2 cases (10%). The percentage of liver steatosis obtained with Oil Red O was consistent in all cases with that of the permanent sections. The staining procedure for Oil Red O required approximately 18 minutes. Conclusions Oil Red O special stain is a fast and inexpensive tool to improve the assessment of steatosis on frozen biopsies during liver transplantation.
- Published
- 2018
10. Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status
- Author
-
Eser Sanverdi, Sotirios Bisdas, Katarina Surlan-Popovic, Sylvie Grand, Gian Marco Conte, Mario Nigro, M. Jorge Cardoso, Maria Vittoria Spampinato, Alexandre Krainik, Diana Roettger, Javier Gonzalez, Nicoletta Anzalone, Jernej Avsenik, Timothé Boutelier, Claudio Ghimenton, Lorenzo Ugga, Valeria Romeo, Arnaud Attyé, Jasmina Panovska-Griffiths, Eftychia Kapsalaki, Arindam R. Chatterjee, Vasileios K. Katsaros, George Stranjalis, Elisa Ciceri, Sebastian Brandner, Elia Guadagno, Francesca B. Pizzini, Andrea Elefante, Carole H. Sudre, Sudre, C. H., Panovska-Griffiths, J., Sanverdi, E., Brandner, S., Katsaros, V. K., Stranjalis, G., Pizzini, F. B., Ghimenton, C., Surlan-Popovic, K., Avsenik, J., Spampinato, M. V., Nigro, M., Chatterjee, A. R., Attye, A., Grand, S., Krainik, A., Anzalone, N., Conte, G. M., Romeo, V., Ugga, L., Elefante, A., Ciceri, E. F., Guadagno, E., Kapsalaki, E., Roettger, D., Gonzalez, J., Boutelier, T., Cardoso, M. J., and Bisdas, S.
- Subjects
Wilcoxon signed-rank test ,DSC-MRI ,Diagnostic machine learning ,Glioma stratification ,Isocitrate dehydrogenase ,Health Informatics ,Machine learning ,computer.software_genre ,Diagnostic tools ,lcsh:Computer applications to medicine. Medical informatics ,030218 nuclear medicine & medical imaging ,Machine Learning ,03 medical and health sciences ,0302 clinical medicine ,Radiomics ,Glioma ,medicine ,Humans ,Grading (tumors) ,Retrospective Studies ,Mri techniques ,business.industry ,Brain Neoplasms ,Health Policy ,medicine.disease ,Magnetic Resonance Imaging ,Subtyping ,Computer Science Applications ,Random forest ,Cerebral blood volume ,Mutation ,lcsh:R858-859.7 ,Artificial intelligence ,Neoplasm Grading ,business ,computer ,030217 neurology & neurosurgery ,Dynamic susceptibility ,Research Article - Abstract
BackgroundMachine learning assisted MRI radiomics, which combines MRI techniques with machine learning methodology, is rapidly gaining attention as a promising method for staging of brain gliomas. This study assesses the diagnostic value of such framework applied to dynamic susceptibility contrast (DSC)-MRI in classifying treatment-naïve gliomas from a multi-center patient pool into WHO grades II-IV and across their isocitrate dehydrogenase (IDH) mutation status.Methods333 patients from 6 tertiary centres, diagnosed histologically and molecularly with primary gliomas (IDH-mutant=151 or IDH-wildtype=182) were retrospectively identified. Raw DSC-MRI data was post-processed for normalised leakage-corrected relative cerebral blood volume (rCBV) maps. Shape, intensity distribution (histogram) and rotational invariant Haralick texture features over the tumour mask were extracted. Differences in extracted features between IDH-wildtype and IDH-mutant gliomas and across three glioma grades were tested using the Wilcoxon two-sample test. A random forest algorithm was employed (2-fold cross-validation, 250 repeats) to predict grades or mutation status using the extracted features.ResultsFeatures from all types (shape, distribution, texture) showed significant differences across mutation status. WHO grade II-III differentiation was mostly driven by shape features while texture and intensity feature were more relevant for the III-IV separation. Increased number of features became significant when differentiating grades further apart from one another. Gliomas were correctly stratified by IDH mutation status in 71% of the cases and by grade in 53% of the cases. In addition, 87% of the gliomas grades predicted with an error distance up to 1.ConclusionDespite large heterogeneity in the multi-center dataset, machine learning assisted DSC-MRI radiomics hold potential to address the inherent variability and presents a promising approach for non-invasive glioma molecular subtyping and grading.Key points-On highly heterogenous, multi-centre data, machine learning on DSC-MRI features can correctly predict glioma IDH subtyping in 71% of cases and glioma grade II-IV in 53% of the cases (87% -Shape features distinguish best grade II from grade III gliomas.-Texture and distribution features distinguish best grade III from grade IV tumours.Importance of studyThis work illustrates the diagnostic value of combining machine learning and dynamic susceptibility contrast-enhanced MRI (DSC-MRI) radiomics in classifying gliomas into WHO grades II-IV as well as across their isocitrate dehydrogenase (IDH) mutation status. Despite the data heterogeneity inherent to the multi-centre design of the studied cohort (333 subjects, 6 centres) that greatly increases the theoretical challenges of machine learning frameworks, good classification performance (accuracy of 53% across grades (87% With its strong generalisability property, its ability to further incorporate participating centres and its possible use to identify borderline cases, the proposed machine learning framework has the potential to contribute to the clinical translation of machine-learning assisted diagnostic tools in neuro-oncology.
- Published
- 2019
11. Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas
- Author
-
Felice Giangaspero, S. Minichillo, Marco Gessi, Elena Zunarelli, Enrico Maria Silini, Claudio Ghimenton, Gianluca Marucci, Antonella Mura, Sofia Asioli, Alexandro Paccapelo, Mariangela Novello, Alicia Tosoni, Enrico Franceschi, Daniela Bartolini, Alba A. Brandes, Marina Paola Gardiman, Stefania Bartolini, Giovanni Lanza, Franceschi E., Tosoni A., Bartolini S., Minichillo S., Mura A., Asioli S., Bartolini D., Gardiman M., Gessi M., Ghimenton C., Giangaspero F., Lanza G., Marucci G., Novello M., Silini E.M., Zunarelli E., Paccapelo A., and Brandes A.A.
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Survival ,Adolescent ,Histopathological grading ,Gastroenterology ,World health ,NO ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Grade II ,Internal medicine ,1p19q codeletion ,Medicine ,Gliomas ,Humans ,In patient ,Grade III ,IDH mutation ,Aged ,business.industry ,Brain Neoplasms ,Hazard ratio ,Glioma ,Middle Aged ,Confidence interval ,Idh mutation ,030104 developmental biology ,Isocitrate dehydrogenase ,Oncology ,030220 oncology & carcinogenesis ,Mutation ,Female ,Neoplasm Grading ,business - Abstract
Background: Diffuse grade II and grade III gliomas are actually classified in accordance with the presence of isocitrate dehydrogenase mutation (IDH-mut) and the deletion of both 1p and 19q chromosome arms (1p/19q codel). The role of tumour grading as independent prognostic factor in these group of tumours remains matter of debate. The aim of this study was to determine if grade is an independent prognostic factor and not somehow associated to IDH mutation and 1p/19q status of the tumour. Methods: We analysed 399 consecutive patients with newly diagnosed, histologically proven World Health Organisation (WHO) 2016 grade II or grade III IDH-mut gliomas, assessed by polymerase chain reaction, immunohistochemistry or next-generation sequencing (NGS). Results: The analysis included 399 patients with grade II (n = 250, 62.7%) or grade III (n = 149, 37.3%) diffuse gliomas. Median follow-up time was 105.3 months. Median survival was 148.1 months. In multivariate analysis, grade II (hazard ratio [HR] = 0.342, 95% confidence interval [CI]: 0.221–0.531; P < 0.001) and 1p/19q codeletion (HR = 0.440, 95% CI: 0.290–0.668; P < 0.001) were independently associated with a lower risk for death. The difference in survival remained significant (p = 0.006 in astrocytomas, p = 0.014 in oligodendrogliomas) when adjusted for histological subtype. Residual disease after surgery (or biopsy) negatively affected survival (HR: 2.151, 95% CI: 1.375–3.367, P = 0.001). Post-surgical treatment with radiotherapy + adjuvant chemotherapy improved survival compared with follow-up and other treatments (HR: 0.316, 95% CI: 0.156–0.641, P = 0.001). Conclusions: In our study, histopathological grade still affects survival in IDH-mutant WHO grade II and III diffuse gliomas. This effect appears to be independent from molecular features, extension of surgical resection and post-surgical treatments. Therefore, physicians should continue to take into account tumour grade, along their molecular characteristics, for a better clinical and therapeutic management of the patients.
- Published
- 2019
12. Donor kidneys with miliary papillary renal cell neoplasia: the role of the pathologist in determining suitability for transplantation
- Author
-
Francesca Fior, Marilena Casartelli Liviero, Matteo Brunelli, Laura Zampicinini, Antonietta D'Errico-Grigioni, Albino Eccher, Luigino Boschiero, Claudio Ghimenton, Anna Caliò, Guido Martignoni, Brett Delahunt, Eccher A, Boschiero L, Fior F, Casartelli Liviero M, Zampicini L, Ghimenton C, D'Errico-Grigioni A, Caliò A, Martignoni G, Delahunt B, and Brunelli M.
- Subjects
Adenoma ,Male ,Pathology ,medicine.medical_specialty ,Tissue and Organ Procurement ,papillary renal cell neoplasia ,renal tumors ,kidney carcinoma ,Renal function ,Kidney ,Gross examination ,Cortex (anatomy) ,Carcinoma ,Cadaver ,Medicine ,Humans ,Carcinoma, Renal Cell ,Kidney transplantation ,Papillary renal cell carcinomas ,business.industry ,TRANSPLANTATION ,Papillary Adenoma ,Kidneys ,General Medicine ,DNA, Neoplasm ,transplantation ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Kidney Neoplasms ,Tissue Donors ,Transplantation ,medicine.anatomical_structure ,business - Abstract
BACKGROUND Kidneys with single or multiple tumors, provided that they have histological features recognized as being associated with low risk of recurrence, are considered suitable for transplantation. It is known that kidneys with multiple primary renal tumors show poor renal function and that function dramatically declines when tumors have a miliary configuration. Despite this, no guidelines are in place to differentiate between multifocal tumors and those that are miliary in nature. CASE REPORT We report a case in which initial examination revealed papillary renal cell neoplasia in deceased donor kidneys, which were later confirmed on histological and genetic testing to be multiple and miliary in distribution. Gross examination showed closely opposed neoplasms, and on histological examination these were found to be papillary renal cell carcinomas and renal papillary adenomas. This ultimately led to the decision that both kidneys were unsuitable for transplantation. CONCLUSIONS At present there are no recommendations as to how tumor-bearing donor kidneys should be handled in order to determine if miliary neoplasia is present. From our case it is apparent that, in addition to obvious tumor nodules, at least 3 samples of cortex should be examined. This case highlights the important role of the pathologist in assessing donor kidneys with evidence of neoplasia.
- Published
- 2014
13. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study
- Author
-
Roberta Bertorelle, Marina Paola Gardiman, Enrico Franceschi, Michele Reni, Alicia Tosoni, Annalisa Pession, P. Iuzzolino, Alba A. Brandes, Mario Ermani, V. Blatt, Claudio Ghimenton, Laura Bonaldi, Giovanna Cavallo, Brandes, Aa, Tosoni, A, Cavallo, G, Reni, M, Franceschi, E, Bonaldi, L, Bertorelle, R, Gardiman, M, Ghimenton, C, Iuzzolino, P, Pession, A, Blatt, V, and Ermani, M
- Subjects
Adult ,Male ,Cancer Research ,Methyltransferase ,Adolescent ,DNA Repair ,Oligodendroglioma ,DNA methyltransferase ,O(6)-Methylguanine-DNA Methyltransferase ,Temozolomide ,Medicine ,Humans ,Anaplastic Oligoastrocytoma ,Promoter Regions, Genetic ,Antineoplastic Agents, Alkylating ,In Situ Hybridization, Fluorescence ,Aged ,medicine.diagnostic_test ,business.industry ,Brain Neoplasms ,Methylation ,DNA Methylation ,Middle Aged ,medicine.disease ,Dacarbazine ,Treatment Outcome ,Oncology ,Chromosomes, Human, Pair 1 ,DNA methylation ,Cancer research ,Female ,Chromosome Deletion ,Neoplasm Recurrence, Local ,business ,Chromosomes, Human, Pair 19 ,medicine.drug ,Fluorescence in situ hybridization - Abstract
Purpose To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy. The aim of this study was to evaluate correlations between 1p/19q deletions, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, and response rate to TMZ in this setting. Patients and Methods From June 2000 to February 2005, 67 patients were enrolled; 39 patients (58%) had AO and 28 patients (42%) had AOA. All patients received 150 to 200 mg/m2 of TMZ every 28 days. Chromosome 1p and 19q deletions were detected by fluorescence in situ hybridization and MGMT promoter methylation was analyzed using methylation specific polymerase chain reaction. Results The overall response rate was 46.3% (17 complete responses and 14 partial responses). The response rate was higher in patients with AO than in those with AOA (61.5% v 25%, P = .003). Combined 1p/19q allelic loss was found in 32 patients (47.8%), while MGMT methylation occurred in 37 (68.5%) of 54 assessable patients. 1p/19q loss was significantly correlated with response rate (P = .04), time-to-progression (P = .003), and overall survival (P = .0001). Despite the significant concordance found between MGMT promoter methylation and 1p/19q deletions (P = .02), MGMT promoter methylation showed only a borderline correlation with overall survival (P = .09). Conclusion TMZ is active in anaplastic oligodendroglial tumors treated at first recurrence. In this setting, 1p/19q allelic loss is an important predictive and prognostic factor. Further studies on MGMT promoter methylation should be performed in randomized trials to test its correlation with survival.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.